GILD · 10-Q · 2026Q3 · Full report
Trodelvy Demand Growth
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 46 · Surprise 56 · No source text
Trodelvy product sales rose 42% to $506 million in the third quarter and 35% to $1.4 billion for the first nine months of 2026. Gilead attributed the growth in both periods primarily to higher demand. The filing also reports expanded first-line triple-negative breast cancer treatment authorizations, including use with Keytruda in eligible patients.
Key facts
- Gilead’s Trodelvy sales increased 42% to $506 million in Q3 2026 and 35% to $1.4 billion for the first nine months of 2026, primarily due to higher demand. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +4.4% | Gilead’s Trodelvy sales increased 42% to $506 million in Q3 2026 and 35% to $1.4 billion for the first nine months of 2026, primarily due… |